Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases

• Status: Recruiting
• Trial end date: 2020-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The Efficacy and safety of Preoperative Intravenous Tranexamic acid versus Sublingual misoprostol in reducing blood loss during and after Elective Cesarean section among high risk pregnant cases.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Misoprostol; Oxytocin; Tranexamic Acid

Criteria

Inclusion Criteria:

• Pregnant women candidate for LSCS.

• Age: 20-40 years old.

• Full term pregnancies (> 37 weeks confirmed by the 1st day of the LMP or 1st trimesteric ultrasound scan).

• Singleton or twin pregnancies.

• Maternal Anemia (hemoglobin < 9.9 g%)

• Maternal medical disorders (e.g. cardiac, renal, and hepatic diseases, Thromboembolic disorders or coagulopathies).

• High risk case for obstetric hemorrhage (e.g. peripartum hemorrhage, accidental hemorrhage, placenta previa, previous history of uterine atony or postpartum hemorrhage).

• CS under spinal anesthesia.

Exclusion Criteria:

• Fetal death (IUFD).

• Fetal anomalies or IUGR (estimated fetal weight below the 5th centile)

• Women attending for emergency CS.

• More than 2 previous CS procedures.

• Prolonged procedure (more than 2 hours from skin incision to skin closure).

• History of prostaglandin or Tranexamic acid allergy.